Mitochondrial-Based Therapeutics – Pipeline Analysis 2019

Press Release

Mitochondrial-based therapeutics pipeline currently exhibits a burgeoning pipeline with 27 drug candidates.

Mitochondria generate adenosine tri-phosphate (ATP) through oxidative phosphorylation, and also plays a key role in apoptosis. Mitochondrial therapeutic development is focused on diseases, which are caused by mutations in mitochondrial deoxyribonucleic acid (DNA) or in nuclear gene encoding mitochondrial protein.

Download free report sample at:

Most of the mitochondrial-based therapeutics drugs are administered through oral route of administration. The intravenous route is the second most common route of administration adopted for administering these drugs, as it is easy to use, improves medication adherence, and ensures high degree of versatility and control.

Various companies are investing in the development of mitochondrial-based therapeutics, and also aim to expand their product portfolio in near future. For instance, in August 2019, Zogenix Inc. acquired Modis Therapeutics Inc. This acquisition aimed to advance Zogenix’s rare disease portfolio of drugs. Through this acquisition, Zogenix Inc. gained license to develop and commercialize drug candidate, MT1621, which is an investigational deoxynucleoside substrate enhancement therapy, for the treatment of mtDNA depletion disorder.

Mitochondrial-Based Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration

This post was originally published on Pharmaceutical Industry